Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):827-836. doi: 10.1016/j.clml.2024.07.011. Epub 2024 Jul 14.
INTRODUCTION/BACKGROUND: Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) have poor prognosis with median survivals of less than 5 years. Although a variety of treatments are approved for MF/SS patients, durable complete remissions (CR) are rare.
Advanced-stage MF or SS patients who achieved CR and maintained in CR or stage IA for more than 10 years were identified by a retrospective search of the principal investigator's database.
Of 2266 patients diagnosed with MF or SS, 23 patients with advanced-stage MF/SS (6 IIB, 1 IIIB, 5 IVA1, 3 IVA2, 8 IVB) who achieved CR and maintained in CR or stage IA for ≥ 10 years were identified. As final/curative treatment, 11 patients underwent allogeneic stem cell transplantation (SCT). Most patients presented at young age, underwent SCT with reduced intensity conditioning regimen, had matched related donors, and controllable post-transplant graft versus host disease. Eleven patients were treated with TSEB as part of combined modality protocol in 2 patients and debulking therapy before allogeneic SCT in 9 patients. Five stage IIB patients achieved CR with radiotherapy. Four patients with blood involvement were treated with extracorporeal photopheresis (ECP) in combination with long-term antibiotics and immunomodulatory agents. Long-term antibiotics were given to 14 patients.
TSEB followed by allogeneic SCT, radiotherapy, ECP plus long-term antibiotics and immunomodulatory agents were the most common curative/final treatments found in our patients. We are reporting the details of our long-term complete responders' treatment course in the hopes of obtaining more cure responses in the future.
简介/背景:晚期蕈样真菌病(MF)和塞扎里综合征(SS)的预后较差,中位生存期不足 5 年。尽管有多种治疗方法批准用于 MF/SS 患者,但很少能达到持久的完全缓解(CR)。
通过回顾性搜索主要研究者的数据库,确定了 23 例晚期 MF/SS 患者(6 例 IIB、1 例 IIIB、5 例 IVA1、3 例 IVA2、8 例 IVB)达到 CR 并维持 CR 或 IA 期超过 10 年。作为最终/治愈性治疗,11 例患者接受了异基因干细胞移植(SCT)。大多数患者年龄较小,接受了强度降低的条件性 SCT,有匹配的相关供体,且移植后移植物抗宿主病可控。11 例患者在 2 例患者中作为联合治疗方案的一部分接受了 TSEB,在 9 例患者中接受了异体 SCT 前的减瘤治疗。5 例 IIB 期患者接受放疗达到 CR。4 例有血液受累的患者接受了体外光化学疗法(ECP)联合长期抗生素和免疫调节剂治疗。14 例患者接受了长期抗生素治疗。
TSEB 后行异基因 SCT、放疗、ECP 联合长期抗生素和免疫调节剂是我们患者中最常见的治愈/最终治疗方法。我们报告了我们长期完全缓解患者的治疗过程细节,希望未来能获得更多的治愈反应。